This year in review of 2024 milestones in non–small cell lung cancer (NSCLC) features coverage of the LAURA trial presented in June at the American Society of Clinical Oncology meeting in Chicago, Illinois, and the EMPOWER-Lung 1 and the Beamion LUNG-1 studies presented in September at the World Conference on Lung Cancer in San Diego, California. It includes updated data from Beamion LUNG-1 shared at the European Society for Medical Oncology (ESMO) Asia meeting held in Singapore in December, as well as an interview with Edgardo Santos Castillero, MD, FACP, on the significance of the Beamion LUNG-1 results. This phase 1a/b dose escalation study examined zongertinib in patients with HER2 mutation-positive NSCLC.
